Interferon-alpha (IFN-α) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway

Clinical and Experimental Immunology

Volumn 118, Issue 1, 1999, Pages 71-77

  Kaser, A ^a   Enrich, B ^a   Ludwiczek, O ^a   Vogel, W ^a   Tilg, Herbert ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Cytotoxicity; Fas ligand; Hepatitis C infection; Interferon alpha; Perforin

Indexed keywords

ALPHA INTERFERON; PERFORIN;

ARTICLE; CELL MEDIATED CYTOTOXICITY; CHRONIC HEPATITIS; COMPLEMENT ACTIVATION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; HEPATITIS C; HUMAN; HUMAN CELL; KILLER CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; T LYMPHOCYTE ACTIVATION;

ANTI-BACTERIAL AGENTS; BLOTTING, NORTHERN; CELLS, CULTURED; CONCANAVALIN A; CULTURE MEDIA, CONDITIONED; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE CULTURE TEST, MIXED; MACROLIDES; MEMBRANE GLYCOPROTEINS; PORE FORMING CYTOTOXIC PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032873591     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.01020.x     Document Type: Article

References (34)

1. 1 Di Bisceglie AM. Hepatitis C. Lancet 1998; 351:351-5.
2. 2 Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26:15-20.
3. 3 Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26:21-28.
4. 4 Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997; 26:71-77.
5. 5 Carithers RLJ, Emerson SS. Therapy of hepatitis C. Meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26:83-88.
6. 6 Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997; 112:1017-21.
7. 7 Berke G. Unlocking the secrets of CTL and NK cells. Immunol Today 1995; 16:343-6.
8. 8 Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370:650-2.
9. 9 Kägi D, Vignaux F, Ledermann B et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265:528-30.
10. 10 Liu CC, Walsh CM, Young JD. Perforin: structure and function. Immunol Today 1995; 16:194-201.
11. 11 Itoh N, Yonehara S, Ishii Aet al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66:233-43.
12. 12 Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169:1747-56.
13. 13 Trauth BC, Klas C, Peters AMet al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245:301-5.
14. 14 Nagata S. Apoptosis by death factor. Cell 1997; 88:355-65.
15. 15 Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391:43-50.
16. 16 Kaser A, Nagata S, Tilg H. Interferon alpha augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression. Cytokine 1999; in press.
17. 1b augments activation-induced T cell death in multiple sclerosis patients. Lancet 1999; 353:1413-4.
18. 18 Kataoka T, Shinohara N, Takayama H et al. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin-and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 1996; 156:3678-86.
19. 19 Tanaka M, Suda T, Haze K et al. Fas ligand in human serum. Nat Med 1996; 2:317-22.
20. 20 Kaser A, Molnar C, Tilg H. Differential regulation of interleukin 4 and interleukin 13 production by interferon α. Cytokine 1998, 10:75-81.
21. 21 Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S. Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 1994; 6:1567-74.
22. 22 Tilg H, Eibl B, Pichl Met al. Immune response modulation by pentoxifylline in vitro. Transplantation 1993; 56:196-201.
23. 23 Neumann AU, Lam NP, Dahari Het al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282:103-7.
24. 24 Mita E, Hayashi N, Iio Set al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994; 204:468-74.
25. 25 Galle PR, Hofmann WJ, Walczak H et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182:1223-30.
26. 26 Hiramatsu N, Hayashi N, Katayama K et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19:1354-9.
27. 27 French LE, Tschopp J. Thyroiditis and hepatitis: Fas on the road to disease. Nat Med 1997; 3:387-8.
28. 28 Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997; 3:409-13.
29. 29 Ruggieri A, Harada T, Matsuura Y, Miyamura T. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology 1997; 229:68-76.
30. 30 Seino K-I, Kayagaki N, Takeda K, Fukao K, Okumura K, Yagita H. Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Gastroenterology 1997; 113:1315-22.
31. 31 Ogasawara J, Watanabe Fukunaga R, Adachi M et al. Lethal effect of the anti-Fas antibody in mice (published erratum appears in Nature 1993 October 1993; 7:365 (6446): 568). Nature 364:806-9.
32. 32 Berke G. The CTL's kiss of death. Cell 1995; 81:9-12.
33. 33 Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388:190-5.
34. 34 Thome M, Schneider P, Hofmann Ket al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997; 386:517-21.